Susquehanna International Group
ACXP icon

Susquehanna International Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Susquehanna International Group’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-525
Closed -$40.2K – 12055
2023
Q4 		$40.2K Buy
+525
New +$39.6K ﹤0.01% 11795

Other funds holding ACXP

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

Susquehanna International Group's ACXP Position: Q4 2025 in Review

Susquehanna International Group sold out of Acurx Pharmaceuticals (ACXP) in Q4 2025, closing a stake of 16,815 shares — an estimated $72.1K sold.

Susquehanna International Group first reported a position in ACXP in Q4 2023 and held it in 5 quarters. The position peaked at $205K in Q4 2023. 18 funds tracked by Wall St. Rank hold ACXP as of Q4 2025.

  • Susquehanna International Group reported no remaining Acurx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 16,815 Acurx Pharmaceuticals shares in Q4 2025, an estimated $72.1K.
  • Susquehanna International Group first reported a position in Acurx Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Susquehanna International Group's Acurx Pharmaceuticals position peaked at $205K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.